Cancer Network Staff

Patients with extensive-stage small cell lung cancer show greater response when atezolizumab is added to carboplatin and etoposide versus placebo in the IMpower133 trial.

Register for CancerNetwork's live, interactive event featuring leaders in oncology reviewing and discussing patient cases in breast cancer.

With the rise of precision oncology, genomic profiling is growing in its utility to support clinical decision making. Lung cancer experts can use this resource to guide therapy selection in NSCLC. Learning more about advancements in this space can improve patient outcomes and advance the field of precision oncology.

The use of PARP inhibitors in frontline maintenance therapy has greatly reduced the risk of recurrence in patients with ovarian cancer.

CancerNetwork® spoke with Ahmet Murat Aydin, MD, about a study designed to evaluate bipolar radiofrequency ablation.

Establishing a multidisciplinary oral chemotherapy clinic in a community hospital is feasible and could help reduce emergency department visits, recognize adverse events earlier, and improve staff and patient satisfaction.

A study found that several disease- and treatment-specific factors are associated with an increased risk of near misses or safety incidents in patients undergoing radiation therapy.

The use of several simple improvement measures including a “chemotherapy huddle” can result in a marked, sustained reduction in chemotherapy errors in a pediatric oncology setting.

A substantial portion of emergency department visits by patients undergoing cancer treatment may be preventable, and those potentially preventable visits account for a high percentage of the emergency department visit costs.

The use of a customized clinical pathways program that helps manage complexity and guide decisions resulted in a sharp decrease in costs per patient in an analysis of stage IV non–small-cell lung cancer.

Undergoing upfront autologous stem cell transplantation is still the preferred treatment of choice for patients aged 65 or younger with newly diagnosed multiple myeloma, according to interim results of a phase III trial.

Early palliative care in cancer patients led to an improvement in depressive symptoms and quality of life among family caregivers.

The physical location of the primary tumor predicts survival in patients with metastatic colorectal cancer, according to an analysis to be presented at ASCO.

Treatment with the anti–PD-1 antibody pembrolizumab yielded good long-term survival outcomes in a phase Ib trial of patients with advanced melanoma.

A meta-analysis of phase I trials found that using biomarker-guided treatment can yield high response rates even in this early phase of drug development.

Researchers identified a novel gene that may predispose individuals to Cowden syndrome, an inherited condition that carries an especially high risk for various epithelial cancers and especially thyroid cancer.

Pembrolizumab, a PD-1 inhibitor, demonstrated better overall survival and progression-free survival vs docetaxel in non–small-cell lung cancer patients.

The overall risk of developing a second primary thyroid or breast tumor is higher in patients with prior breast or thyroid cancer.

A treatment strategy including dose intensification with interval compression, use of the most active agents available, and the use of irinotecan as a radiation sensitizer led to a promising event-free survival rate in certain patients with metastatic rhabdomyosarcoma.

The FDA announced the approval of trabectedin (Yondelis) for the treatment of liposarcoma and leiomyosarcoma that is either unresectable or has metastasized.

In patients with chronic myeloid leukemia (CML), a prospective, long-term study has found that hematopoietic stem cell transplantation (HSCT) and drug therapy yielded similar 10-year survival outcomes.

The US Food and Drug Administration announced an expanded indication for the Optune device to treat newly diagnosed patients with glioblastoma multiforme.